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Abstract
This research aimed to synthesize and characterize Zn2+-ligand complexes that have the
same zinc coordination environment as in histone deacetylase (HDAC) and other important zincdependent enzymes. Mimicking the structural and the functional properties of Zn2+-enzymes will
allow us to understand the binding reactivity between Zn2+ and small molecule enzyme
inhibitors. The new understanding will help to develop new approaches to target disease states
such as cancer. A variety of Zn2+ binary complexes have been synthesized and their interactions
with inhibitors such as suberanilohydroxamic acid (SAHA) and 8-Hydroxyquinoline (8HQ) have
been studied using 1H NMR, UV-Vis, and fluorescence spectroscopies. Attempts were made to
mimic the structure of Zn2+-metalloenzyme active sites by exploring several different supporting
ligands to model enzyme active sites. We endeavored to mimic an “O2N” ligand set of HDAC by
using reported Zn2+-complexes ligated by Bis(phenolato)amine (H2L1), Bis(2-picolyl) amine
(BPA, L2), hydrotris(3-phenyl-5-methylpyrazol-1-yl) (TpPh,Me, L3), and a similar neutral ligand
(L4). The binding constants of the ligands with zinc were estimated using UV-Vis studies and
calculations based on equilibrium expressions. This data was compared with previously reported
data using other methods such as potentiometry and isothermal titration calorimetry.
Once the zinc-ligand complexes were obtained, they were examined for mimicking zinc
active sites. Attempts were made to study the interaction of inhibitors with the zinc center using
1

H NMR, UV-Vis, and fluorescence spectroscopies. In addition, the functional properties of the

mimicked structure were explored by attempting to cleave the amide group of a model substrate
for HDAC, N-acetylbenzylamine. Although the Zn2+ species were not active, Al 3+ was observed
to cleave the amide group at high temperature after extended periods of time. The zinc-ligand
8

structures were also examined using computational methods to support the experimental data.
The results of this work are valuable complementary data to previously reported ITC data and
the known biological systems.
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Chapter 1. Introduction
Zinc plays a variety of critical roles in biology. An average adult human body contains 3
grams of zinc, present in all body muscle tissue, and in higher concentrations in various organs
such as prostate and eye tissue (retina and choroids).1 Zinc is the second most abundant
transition metal in our bodies after iron.2 In medicine, zinc is important because it has been
shown to help prevent the effects of infectious diseases such as malaria and pneumonia, and to
shorten the length of common cold in adults.1 At a molecular biology level, zinc is an essential
component in approximately 300 enzymes within six main classes: oxidoreductases, transferases,
hydrolases, lyases, and isomerases.3,4 These zinc-dependent enzymes play a significant role in
the progression of human diseases. For example, zinc is indispensable for the effective growth
and development of cancer cells. Thus, zinc-containing enzymes are potential targets for the
treatment of cancer in humans.
In metal-based enzymes, the binding between the metal in the active site and various
ligands such as substrates or inhibitors depends on many factors. It is often useful to invoke the
“Hard-soft acid-base” (HSAB) theory, in which strong bonding occurs when a hard acid and
hard base or a soft acid and soft base interact. Zinc is a “borderline” metal, which means the
interactions between the Zn and both hard and soft donor atoms in the ligand are equally
favorable.4 Likewise, the divalent d10 Zn2+ ion is exceptionally stable with respect to oxidation
and reduction under biological conditions, and so does not participate in redox reactions, as
compared to the redox-active biological metals Mn, Fe, and Cu. Zinc often plays a role of
activating reagents via donor-acceptor interactions. One classic example of an enzyme with a
zinc atom in its active site is carbonic anhydrase (CA). The carbonic anhydrase enzymes are
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oldest known class of Zn metalloenzymes, which was discovered in 1940 by Brinkman et al
(Figure. 1.1).5

Figure 1. 1. Carbonic anhydrase II (CA). Image from the RCSB PDB of PDB ID 5J8Z, and
generated by PyMol. The upper Figure shows the binding between the Zn and three histidines,
and the second figure shows a carbonic anhydrase inhibitor binding with Zn2+.1

The CA enzyme contain four ligands binding with Zn2+ in the resting state of the catalyst, three
Histidine residues (His) and a nucleophilic, activated hydroxide molecule occupies the fourth
coordination site, providing a distorted tertahedral geometry.6 Human CA plays an important role
in regulation the pH and fluid balance in different parts of human body.7 It catalyzes the
reversible hydration of bicarbonate ion to form carbon dioxide, as per the following reaction:
CO2 + H2O ⇌ HCO−3 + H+
The inhibition of human CA can have harmful effects on the body in the form of acidosis as
blood pH homeostasis is disrupted.8 The tetrahedral coordination in Zn and the surrounding
11

amino acids enhance both the Lewis acidity of the zinc center and the Brønsted acidity of a
coordinated water molecule.6 Ligand field stabilization effects do not influence zinc complexes
due to the d10 configuration of Zn2+, and so coordination number and geometry are quite flexible
and are only affected by ligand size and charge. Hydrolytic Zn-enzymes are capable of
hydrolyzing a variety of strong bonds, such as hydrating CO2 in carbonic anhydrase, cleaving
amide bonds (RC(O)-NHR′ ), or cleaving a phosphate bond.1
Amide bonds are very stable in biology, but they can be hydrolyzed by Zn-dependent
enzymes. Each particular amide hydrolysis enzyme targets a specific type of amide bonds. For
example, carboxypeptidase hydrolyzes the C-terminus in a peptide residue, collagenase
hydrolyzes collagen, dipeptidase hydrolyzes dipeptides and Histone Deacetylase (HDAC)
hydrolyzes an acetamide group of a lysine residue on a Histone protein (Figure 1.2).9 One
approach to the development of cancer drugs is targeting the enzymes that allow the uncontrolled
replication of cancer cells. Histone deacetylase enzymes (HDAC) are one class of these targeted
enzymes. Inhibiting these enzymes prevents the remove of the acetyl groups on N-acetyl lysine
residues in histone proteins.10 Deacetylation plays an important role in many gene regulations,
especially regulation of gene transcription. Histone components are present in the core of
chromatin in DNA, and they control transcription and play an essential role in gene regulation.

12

Figure 1.2. The deacetylation by HDACs of the acetyl group from lysine in the presence of
water, releasing an acetate molecule.

The nucleosome is the fundamental unit of chromatin and it is composed of an octamer of
the four core histones (H3, H4, H2A, H2B) around which 147 base pairs of DNA are wrapped
(Figure1.3).11 The histone is important for establishing different ionic interactions between
nucleosomes in chromatin. Therefore, chromatin can adopt different structural conformation
depending on modifications that occur in the histone tails, specifically H-3 and H-4, which are
targeted for various post-translational modifications such as acetylation, N-methylation, or
phosphorylation.12 The mechanism of gene-transcription includes neutralizing the positive
charge of histone lysine residues in order to result in more relaxed chromatin. Deacetylation of
histone lysine residues increases ionic interactions between positively charged histones and
negatively charged DNA, resulting in condensed chromatin and limiting gene transcription.

13

Figure 1.3. The nucleosome is the basic unit of chromatin and it consists of DNA wrapped
around a histone octamer.2

Histone deacetylases comprise a family of 18 enzymes, which are grouped into classes I–
IV based on their homology to their respective yeast orthologues. Classes I, II and IV contain 11
family members, which are referred to as classical HDACs; the other 7 members are in class III
which are called sirtuins. Studies have shown that the classical HDACs are promising targets for
anti-cancer drugs.12 Inhibition of HDACs can be used as a therapeutic approach to prevent
deacetylation thus prevent cancer cells from replicating genes, and eventually killing them.
Classes (I\II) show effective targets toward inhibiting cancer cells. In these two classes, a wide
range of HDAC enzymes share the same structural characterization, which comprise of a zinc
active site at the bottom of a tubular pocket.
In HDAC, zinc is coordinated by two His residues and an aspartate residue as well as a
water/hydroxide. It has been well recognized that certain histone deacetylase enzymes inhibitors
14

(HDACI) are promising cancer therapeutic agents.10,12,13 These inhibitors act by binding the
HDAC, thus modifying gene expression to restore the normal differentiation or kill the programs
of transformed cells. Several HDACIs have been isolated as natural or synthesized products.
HDACs have been classified into 3 classes (I\II) NAD- dependent and class (III) (HDAC)
Histone deacetylase enzyme. One example of a good HDAC inhibitor is suberanilohydroxamic
acid (SAHA, also known as Vorinostat), which contains a zinc-binding group connected to an
aliphatic chain and a capping group (Fig. 1.4).14,15 These three general components can also been
found in several other HDACIs.

Figure 1.4. The Structure of Vorinostat (SAHA) and the general structure of HDACIs.
Three general regions that many HDACIs are comprised of: a cap, an aliphatic chain, and a zincbinding group.
Vorinostat (SAHA) was the first drug approved by the FDA as a treatment for cutaneous
T-cell lymphoma and is an effective HDACI.13 In addition to targeting cancer cells, HDACIs
including SAHA have been identified as potential treatments of metabolic diseases,
inflammatory diseases, neurodegenerative disorders, and cardiovascular disease. Another
inhibitor used in this study was 8-Hydroxyquinoline (8HQ) (Figure 1.5). 8HQ is a
15

monohydroxyquinoline compound, which are found in plants and have a variety of known
synthetic variants. It is a well-known strong chelator of metal ions with the ability to bind Zinc.
It is worth noting that 8HQ derivatives also have pharmacological application to a wide range of
diseases, such as HIV, breast cancer, prostate cancer, and fungal infections.9

Figure 1.5. The 8-Hydroxyquinoline (8HQ) structure.

Although some progress has been made to understand drug-zinc interactions, a better
understanding of the specific interactions between the zinc active site and the drug molecules is
needed in order to design better drugs to treat cancers and other disorders. However, it is very
difficult to work with the native enzymes, as they are time-consuming and challenging to
produce in large amounts. In addition, the large size of enzymes makes spectroscopic techniques
that target the active site difficult to perform and interpret. Instead, we chose to attempt to mimic
the active site of the zinc enzymes by synthesizing small zinc-containing molecules that are
models of the active site structures. Mimicking the structural and the functional properties of Zn
enzymes will allow us to understand the binding reactivity between Zn2+ and its inhibitors and
that new understanding will lead us to develop new techniques to deliver inhibitors or drugs to
cancer cells. A variety of zinc complexes and their interactions with inhibitors such as SAHA
and 8HQ have been studied.1-4,6,10-13 Previously, the interactions between zinc and various
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ligands and inhibitors were examined in solution using isothermal titration calorimetry (ITC) in
Dr. Jin’s lab in collaboration with Dr. Karver and Dr. Grice.16
In this work, several attempts were made to mimic the structure of Zn2+ metalloenzyme
active sites shown in Figure 1.6 using complementary techniques to ITC to obtain more
information. We explored different supporting ligands to examine the active site structures
including methylamino-N,N-bis(2-methylene-4.6-di-tert-butylphenolato) (H2L1), bis(2-picolyl)
amine (BPA, L2), hydrotris(3-phenyl-5-methylpyrazol-1-yl) (TpPh,Me, L3), and a similar neutral
ligand (L4) (Figure 1.6). in previous work, complexes of BPA and TpPh,Me have been examined
for mimicking zinc active sites.13,16 In addition, the x-ray structures of Zn(L2) and Zn(L3)
complexes are known.13,16,17 The zinc complexes of these ligands were synthesized and then used
in further studies (Figure 1.7). Given the small size of these complexes relative to the actual
enzyme, we were able to study the interaction of enzyme inhibitors with the zinc center and also
to characterize the functional properties of the mimicked structure by attempting to cleave a
model amide group. More importantly, we studied the interaction of Zn2+-ligands towards
inhibitors of histone deacetylase, such as Vorinostat (SAHA) and 8-hydroxyquinoline (8HQ).
The results of this study are reported in the following chapters. Chapter 2 reports the
experimental details of the studies. Chapter 3 reported the studies of the interaction between Zn2+
and the ligands in Figure 1.6, and the functionality of these complexes (Figure 1.7). Chapter 3
also studies of the interaction of inhibitors with the Zn2+-ligand binary complexes that had been
previously identified as potential HDAC structural mimetics. Lastly, chapter 4 reports the
interaction between Zn2+ and ligands and between Zn2+ and inhibitors using UV-Vis and
fluorescence spectroscopies.
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Figure 1. 6. Ligands explored in this work. On the top right is a benzyl-stubstituted
bis(phenolato)amine (H2L1), L2 is bis(2-picolyl)amine (BPA), L3 is hydrotris(3-phenyl-5methylpyrazol-1-yl) (TpPh,Me), and L4. The atoms that can bind to metals are highlighted in blue.

18

Figure 1.7. Zinc Complexes of Ligands L1, L2, L3 and L4. The image shows the general
expected bonding patterns for these complexes. L and X refer to generic neutral and anionic
ligands, respectively.
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Chapter 2. Experimental methods
2.1. General considerations
All reactions and processes were carried out on the benchtop in the presence of air unless
otherwise noted. Zn[N(TMS)2]2 was purchased from Sigma Aldrich, and BPA ( ˃ 98.5%) was
purchased from TCI. All other reagents and solvents were purchased from commercial suppliers
and used as supplied. All NMR spectra were collected using a Bruker Avance 300 MHz NMR
spectrometer at 298 K. 1H NMR spectra were referenced against residual solvent peaks and
reported downfield of tetramethylsilane (δ = 0 ppm). UV–Visible (UV–Vis) spectra were
obtained with a Varian Cary 100 UV–Vis spectrometer. Infrared (IR) spectra were collected on
an ABB FTLA2000 IR spectrometer equipped with a PIKE Technologies MIRacle diamond
ATR (attenuated total reflectance) anvil. Fluorescence spectra were obtained with a Varian Cary
Fluorescence spectrophotometer.
2.2. Preparation of the Ligands, Zn-ligands, and reactions of (ZnL) with inhibitors
2.2.1. Synthesis of H2L1
The methylamino-N,N-bis(2-methylene-4.6-di-tert-butylphenolato) (H2L1) was
synthesized in two steps based on a modification of the procedure by Silvernail C. and coworkers. A solution of methylamine (7.5 ml, 0.2 mol) was added dropwise at 0 °C to a stirring
solution of paraformaldehyde (5.2 g, 0.2 mol) and KOH (0.01 g, 0.2 mol) in 25 ml of ethanol.
After the mixture was allowed to warm to room temperature, a second solution of 2,4-di-tertbutylphenol (35.5 g, 0.2 mol) in 25 ml ethanol was added to the first mixture in one portion. The
reaction was heated to reflux for 24 h. After allowing the reaction to cool, the solvent was
removed under vacuum, and the product was rinsed with 20 mL of ethanol. The final product
was a white solid (2.11 g, 3.4%). NMR data matched literature values.3
20

2.2.2. Synthesis of [Zn(L1)]2
[Zn(L1)]2 was prepared by adding Zn[N(TMS)2]2 (0.3 ml, 5.7 mmol, TMS =
trimethylsilyl) to a stirring solution of H2L1 (70 mg, 5.7 mmol) in 5 ml toluene. The green
mixture was stirred at room temperature for 16 h. A light green powder (0.03 mg, 43%) was
obtained after washing the product with 5 ml pentane. 1H NMR (300 MHz, CD2Cl2): δ = 5.32 (s,
2H), 7.30 (s, 2H, PhH), 7.09 (s, 2H, PhH), 7.02 (s, 2H, PhH), 6.70 (s, 2H, PhH), 4.98 (d, J) 13
Hz, 2H, CH2), 3.90 (d, J) 13 Hz, 2H, CH2), 3.40 (d, J) 13 Hz, 2H, CH2), 2.57 (d, J ) 13 Hz, 2H,
CH2), 1.39 (s, 18H, t Bu), 1.29 (s, 18H, t Bu), 1.20 (s, 18H, t Bu), 1.18 (s, 18H, t Bu).
2.2.3. Reaction of [Zn(L1)]2 with suberanilohydroxamic acid (SAHA)
[Zn(L1)]2 (0.3 g, 0.02 mmol) and SAHA (6.5 g, 0.02 mol) were dissolved in 10 ml
acetonitrile. The reaction was stirred for 24 h in a 60 °C oil bath, and then the solvent was
removed under vacuum. Crystallization was attempted using vapor diffusion by dissolving the
product in methanol and placing the vial in a larger vial filled with pentane. The product did not
crystallize, therefore the solvent was removed under vaccum and the mass of the solid was
obtained (44.1 mg, 86.5%). IR and 1H NMR spectra are shown in chapter 4.
2.2.4. Reaction of [Zn(L1)]2 with 8-hydroxyquinoline (8HQ)
[Zn(L1)]2 (50 mg, 0.04 mmol) and 8HQ (5.9 mg, 0.04 mmol) were dissolved in 5 ml
acetonitrile. As soon as 8HQ was added, the color of the mixture turned to yellow. The reaction
was stirred for 24 h in a 60 °C oil bath. The product was then dried using a rotary evaporator,
resulting in a yellow power with a 0.05 g yield (85.7%). 1H NMR spectra are shown in chapter 4.
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2.2.5. Synthesis of Zn(L2)Cl2
A sample of commercially purchased bis(2-picolyl)amine (BPA, L2) (0.25 ml, 0.1 mmol)
was added to stirring solution of (17 mg, 0.1 mmol) of zinc dichloride and 5 ml methanol. The
reaction as heated at 60 ºC for 24 h. The product was filtered and dried. Spectral data matched
literature values.16
2.2.6. Reaction of Zn(L2)Cl2 with 8HQ
A sample of Zn(BPA)Cl2 (0.8 mg, 3.4 mmol) and 0.5 mg (3.4 mmol) of 8HQ were
dissolved in 5 ml acetonitrile (ACN). The reaction was stirred in 60 ºC oil bath for 48 h. the 1H
NMR spectra are shown in chapter 4.
2.2.7. Previous syntheses of Zn(L3)OH, Zn(L3)(8HQ), and L4
Zn(L3)OH and Zn(L3)(8HQ) were previously prepared in Dr. Grice’s lab by other
researchers.13 The ligand L4 was prepared by Mark Gudger in the Grice lab and characterized by
1

H and 13C{1H} NMR as well as X-ray crystallography and elemental analysis (unreported data).

2.3. Other experimental details
2.3.1. Attempted synthesis of a benzylated version of H2L1
An attempt was made to synthesize a benzylated version of H2L1, benzylamino-N,Nbis(2-methylene-4.6-di-tert-butylphenolato). A solution of benzylamine (9.45 ml, 0.1 mol) was
added dropwise at 0 ˚C to a stirring solution of paraformaldehyde (5.2 g, 0.2 mol) and KOH
(0.077 g, 1.2 mmol) in 25 ml of ethanol. After the mixture was warmed to room temperature, a
second solution of 2,4-ditertbutylphenol (35.5 g, 0.2 mol) in 25 ml ethanol was added to the first
mixture in one portion and the reaction was heated to reflux for 24 h. After allowing the reaction
to cool, the solvent was removed under vacuum, and the product was rinsed with 20 mL of
22

ethanol. The final product was a white solid (18.8 g, 89.9%). 1H NMR (300 MHz, CDCl3): δ =
7.20 (m, 5 H, Ar), 7.07 (d, JHH = 2.80 Hz, 1H, Ar), 6.67 (d, JHH = 2.21 Hz, 1 H, Ar), 4.71 (s, 2 H,
NCH2O), 3.90 (s, 9 H, ArCH2N), 3.80 (s,2 H, CH2Ph), 1.70 ((s, 2, C(CH3)3), 1.30 ((s, 2,
C(CH3)3) ppm.18 When comparing these spectra with the spectra for H2L1, it showed different
signals than would be expected for the desired product. Therefore, the final product is not of the
fomula H2L, but rather using benzylamine as a starting material yielded a benzoxazine product
(Scheme 2.3.1).

Scheme 2.1. Benzoxazine synthesis. This reaction occurred during instead of the desired ONO
ligand (a derivative of H2L1).
2.3.2. Alternative synthesis of [Zn(L1)]2
An alternative approach was performed by using a different Zn-containing species as a
starting material. Zn(OAc)2·2H2O (21 mg, 0.1 mmol) was added to a stirring solution of (70 mg,
0.1 mmol) (H2L1) and 5 mL toluene. The reaction was stirred for 14 h at ambient temperature.
Then, the solvent was evaporated to dryness on rotary vaporator and a light green solid was
formed. 1H NMR (300 MHz, CDCl3): 7.24 (s, 2H, PhH), 7.23 (s, 2H, PhH), 7.18 (s, 2H, PhH),
7.16 (s, 2H, PhH), 4.86 (s, 2H, CH2), 4.63 (s, 2H, CH2), 3.64 (s, 2H, H2O), 3.45 (s, 2H,CH2),
2.33 (d,J 13 Hz, 2H, CH2), 2.11 (s, 3H, CH3), 12.03 (s,18H, tBu), 1.40 (s, 18H, tBu), 1.28 (s,
18H, tBu), 1.25 (s, 18H, tBu).
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2.3.3. Reaction of [Zn(L1)]2 with SAHA and base
Suberanilohydroxamic acid (10.8 mg, 0.4 mmol), a sample of KOH (2.3 mg, 0.04 mmol)
and 18-crown-6 (10 mg, 0.03 mmol) were added to 7 ml methanol. The reaction was allowed to
stir until complete dissolution. Next, 50 mg (0.04 mmol) of [Zn(L1)]2 was added to the reaction,
then it was allowed to stir at room temperature for 24 h. The solution was evaporated to dryness
on a rotary vaporator, and a white solid was recrystallized from tetrahydrofuran (2 ml). However,
the solid did not precipitate and therefore the solvent was removed. 1H NMR spectra was taken,
and showed tert-butyl signals at the shifts of δ = 1.39 (s, 18H, tBu), 1.29 (s, 18H, tBu), 1.20 (s,
18H, tBu), 1.18 (s, 18H, tBu).
2.3.4. Attempted deprotonation of SAHA
Suberanilohydroxamic acid (SAHA) (0.2 g, 0.7 mmol) was added to 5 ml methanol. In
the same mixture, 18-crown-6 (0.2 g, 0.7 mmol) and KOH (0.04 g, 0.7 mmol) were added. The
reaction was allowed to stir at room temperature for 3 h. the solution was evaporated to dryness
on a rotary vaporator. The resulting compound was a clear oil. 1H NMR (300 MHz, CDCl3) δ =
7.72 (d, 2H), 7.03 (t, 1H), 2.37 (t, 2H), 2.19 (t, 2H), 2.00 (s, 1H), 1.87 (d, 1H), 1.74 (t, 2H), 1.64
(t, 2H), 1.40 (s, 2H). THF (2 ml) was added; however, the solid only partially dissolved.
Therefore, the mixture was separated by glass wool into a solid and a solution. The solid was
recrystallized in THF by allowing pentane to vapor diffuse into the solution. However, a yellow
semi-crystalline viscous material was produced instead of crystals. The solution was evaporated
to dryness and the residue was dissolved in methanol. Pentane was allowed to vapor diffuse into
methanol. Small particles were observed and the product was washing four times with THF to
yield a white solid (1.6 mg, 0.4%). The characteristic IR peaks for (O-H) and (N-H) in SAHA
are: 3286, 3251 and 3137 cm-1. As in this range, it was hard to differentiate the (O-H) bands
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from the (N-H) bands. In comparison, the IR spectra for deprotonated SAHA shows one band at
3306 cm-1. The lack of the broad band in the same region indicates that SAHA might be
protonated. T 1H NMR showed that this material matched SAHA, and the IR spectra displayed a
broad band for (O-H) that differed from SAHA’s IR spectra and the deprotonated IR spectra.
Together, this indicates that deprotonation did not occur.
2.3.5. Reaction of [Zn(L1)]2 with 8HQ
A sample (31 mg, 0.05 mmol) of [Zn(L1)]2 was added to 5 ml chloroform-d. In the same
solution, 8.3 mg (0.05 mmol) of 8HQ, 0.31 mg (0.05 mmol) of KOH, and 15 mg (0.05 mmol) of
18-crown-6 were added. The reaction stirred for 24 h in ambient temperature. The solution was
evaporated to dryness.
2.4. Attempted hydrolysis of amide bonds
Several Zn-ligand complexes were examined as catalysts to hydrolyze a secondary amide
bond in a small molecule substrate. The general procedure was as follows: 1 equivalent of Znligand species and one equivalent of N-benzylacetamide (the substrate) were dissolved in
dimethyl sulfoxide-d6 (DMSO-d6) and water (1:1 solution). The mixture was heated and stirred
in an oil bath at 100 °C for a long period of time (several days). 1H NMR spectra were collected
for each reaction and are shown in Chapter 3. The1H NMR spectra of benzylamine and Nphenylacetamide were taken to compare with the spectra of the reactions of each ZnL. 1H NMR
(300 MHz, DMSO) for benzylamine: δ =7.21-7.37 (s, 5 H, Ph), 3.87 (s, 2H, CH2) and 1.41 (s,
2H, NH2). 1H NMR for N-phenylacetamide (300 MHz, DMSO) δ = 7.31 (s, H, NH), 7.29 (s, 2H,
Ph), 7.25 (s, 2H, Ph), 7.23(s, H, Ph), 4.25-4.23 (d, 2H, CH2), 1.86 (s, 3H, CH3).
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2.5. UV-Vis analysis of the interaction between Zn2+, Ligands and inhibitors
Different concentrations of Zn-ligand complexes were dissolved in 5 ml acetonitrile
(ACN). We attempted this process for all ZnL species reported in this thesis. The Varian UV
Scan software was used to collect the data. Quartz cuvettes were used in order to avoid
dissolving plastic cuvettes with organic solvents. In addition, different concentrations of
Zn(L2)Cl2 were dissolved in 5 ml buffer solution (50 mM NEM, 0.15 M NaCl, pH 6.8). After
taking the spectra of Zn-ligand complexes, a fixed amount of ZnCl2 (7 mg) was added to the
measured solution of Zn-ligand. Then, the spectra of (ZnL) and the additional ZnCl2 was taken.
Spectra are shown in chapter 4 section 4.1.
2.6. Fluorescence analysis of the interaction between Zn, ligands and inhibitors
The maximum fluorescence emission wavelengths of Zn-ligands and inhibitors were
collected using excitation wavelengths at 240 nm, 260 nm and 310 nm. We used these
wavelengths to determine the emission spectra of each Zn-ligand-inhibitors species. The
software used was Cary Eclipse Scan. The general procedure involved using a small amount of
Zn-ligand (ca. 1 mg) and inhibitor dissolved in 5 ml acetonitrile. Spectra are shown in chapter 4.
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s oep h ni ht3p CtC ar tt3 Ce t C o3e p th t3p ho pta3 ttp t3 tetpahC, o3e assessment of
tehattCtC o ptrtpt
The focus of this project was to form mimetic complexes of the HDAC active site and
study their interactions with different HDAC inhibitors. The design of the Zn-ligand complexes
must obey certain requirements to be qualified as mimicking zinc enzymes active sites. Previous
ITC studies of the interaction of Zn2+_with several ligands indicate that for a successful mimetic,
the ligand must strongly chelate to Zn2+, form a complex with a zinc-to-ligand ratio of 1:1, and
still have open coordination sites for the inhibitor to interact.16 Zn2+ coordination complexes can
exist in solution with tetrahedral, trigonal bipyramidal, or octahedral geometries. The tetrahedral
and trigonal bipyramidal geometries are particularly preferred by Zn2+, and provide only four or
five total coordination sites, respectively. Therefore, using tetradentate or pentadentate ligands to
form the zinc:ligand complex leads to insufficient coordination sites left on Zn2+ for the inhibitor
binding.16 Both inhibitors used in this study are bidentate chelating ligands, which makes them
good inhibitors to bind metals in enzyme active sites because their coordination will be stabilized
by the chelate effect. In this chapter the synthesis of zinc enzyme active site mimics are reported
along with their interaction with enzyme inhibitors, as studied by NMR spectroscopy. The ability
of the zinc complexes to act as functional mimics of HDAC is also explored. Finally,
computational calculations were performed to optimized Zn(L1) and Zn(L1)(AHA) structures.
3.1. Ligands with O, N, O coordination framework
3.1.1. Synthesis of H2L1 and its zinc binary complex
Given that the coordination geometry of the HDAC active site contains two aspartates
and a histidine residue, we sought to mimic this with a tridentate ligand with one nitrogen and
two oxygen donors. Methylamino-N,N-bis(2-methylene-4,6-di-tert-butylphenol (H2L1) is a
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tridentate ligand that can bind to transition metal ions such as Zn2+ (Figure 1.6). The [Zn(L1)]2
complex was studied by Silvernail C. M. and co-workers using 1H NMR, 13C NMR spectroscopy
and X-ray crystallography.3 H2L1 was prepared by a condensation of methylamine,
paraformaldehyde and tert-butylphenol in refluxing methanol. Then, the addition of
Zn[N(TMS)2]2 resulted in a dimeric complex, [Zn(L1)]2. In the solid state, the complex
possesses a dinuclear structure with each Zn2+ ion coordinating two oxygens and one nitrogen of
each bis-phenolate amine and coordinating to an oxygen of a second molecule of the Zn(L1)
monomer. However, it has been reported that in solution such as tetrahydrofuran-d8, this dimeric
compound is in equilibrium with a monomeric solvent-bound structure (Scheme 3.2). In addition
to following the reported synthesis, we found that the specialized reagent Zn[N(TMS)2]2 was not
necessary for synthesis of [Zn(L1)]2. The cheaper and less sensitive salt Zn(OAc)2·2H2O was
equally effective in reaction with H2L1.
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Scheme 3.1. Synthesis of methylamino-N,N-bis(2-methylene-4,6-di-tert-butylphenol (H2L1)
and its reaction with a Zn2+ source.

Scheme 3.2. The equilibrium equation between the dimeric complex [Zn(L1)]2 and the
monomeric complex in the presence of a donor ligand.
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3.1.2. Attempted synthesis of a benzylated version of H2L1.
We attempted to synthesize a variant of H2L1 by using benzylamine instead of
methylamine. Unfortunately, the desired ligand was not produced. Instead, a cyclic benzoxazine
was formed (see section 2.2.1). It was surprising that such a minor modification of the starting
material led to such a different product.
3.1.3. Synthesis of a bis(2-picolyl)amine (BPA) complex of Zn2+
Commercially available bis(2-picolyl)amine (BPA, L2) was also studied as a potential
ligand to develop an zinc-enzyme active site structural and functional mimetic. BPA has been
identified as a promising ligand in ITC studies. BPA is a tridentate ligand that can potentially
bind Zn2+ with two pyridine nitrogen atoms and the nitrogen of the secondary amine. The
Zn(BPA)Cl2 was synthesized at 60 °C using commercially purchased bis(2-picolyl)amine and
zinc dichloride dissolved in methanol. The product was isolated and was confirmed as
Zn(BPA)Cl2 by obtaining spectral data that matched literature values.16 Zn(L2)Cl2 is well known
and its crystal structure has been reported.17 No evidence was observed for other binding modes
of BPA (such as a 2:1 BPA:Zn ratio) in the sample of Zn(L2)Cl2 that was synthesized and used
in the studies.

Scheme 3.3. The reaction of the tridentate bis(2-picolyl)amine (BPA) and ZnCl2.
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3.1.4. Previously synthesized (ZnL) Species
Zn(TpPh,Me)OH and Zn(TpPh,Me)(8HQ) have been previously reported in the Dr. Grice
group and were used in this study.13 In addition, a previously unreported ligand (L4) and its zinc
complex were also examined. L4 was synthesized by Mark Gudger in the Grice lab according to
the following reaction and has been characterized by 1H NMR, elemental analysis and X-ray
crystallography (unreported data).

Scheme 3.4. The synthesis reaction of L4. The nitrogen atoms in blue in L4 are the donors
in the ligand that coordinate to Zn2+.

3.2. Examining the hydrolytic activity of Zn-ligand complexes
The amide bond is ubiquitous in nature. They are the key chemical linkages in peptides
such as proteins, enzymes, and antibodies. The resonance structures of amides explain many of
the properties of this functional group, such as the short (N−C(O)) bond length, barrier to
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N−C(O) rotation, planar geometry, IR stretching frequencies, 13C NMR chemical shifts, and
resistance toward nucleophilic attack.19 Most biological reactions are catalyzed by enzymes,
including hydrolysis of proteins, fats and carbohydrates. Although amides can readily be cleaved
by enzymes such as proteases, it is difficult to selectively break the carbon–nitrogen bond of an
amide using standard organic chemistry.20 Transition-metal-catalyzed cleavage of inert chemical
bonds such as C−H, C−C, and C−O bonds is an important area of organic chemistry and
organometallic chemistry.
The cleavage of amide C−N bonds, especially by transition-metals, was initially reported
in 1980, and has become an area of focus since 2010. It provides a mild and convenient approach
to obtain nitrogen and/or carbon sources for the synthesis of valuable products.21 Here we
attempted to determine if amide carbon–nitrogen bonds can be activated and cleaved using
ligand-Zn2+ binary complexes that had been identified as potential HDAC structural mimics. We
wished to determine if the Zn-ligand complexes have the ability to function as an enzyme.
Transition-metal-catalyzed C−N bond cleavage is classified into five approaches: (1) via
oxidative addition of transition-metal catalysts to C−N bond, (2) via imine or iminium species,
(3) via ammonium species, (4) via β-amino elimination, and (5) via insertion/deinsertion.21 Two
types of C−N bonds, including the amide C−N bond and the non-carbonyl C−N bond, are
involved in an amide molecule. Generally, the amide C−N bond is considered to be more
reactive than the non-carbonyl C−N bond. Another factor to consider in this process is sterics.
An amide bond that is less sterically hindered by substituents is more likely to be cleaved.22 In
Scheme 3.5 the mechanism of hydrolyzing an amide bond by a Zn-ligand complex with a bound
hydroxide is shown.
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Scheme 3.5. The mechanism of hydrolyzing an amide bond by a Lewis acidic Zn2+.

We used N-benzylacetamide as a model for the substrate of Histone Deacetylase. The
hydrolysis of benzylacetamide was not successful at room temperature. Therefore, the reaction
was performed in an 100 ºC oil bath with a variety of catalysts. The 1H NMR spectra of the
solutions were collected at different times of the reaction (Scheme 3.6).

Scheme 3.6. The hydrolysis reaction of benzylacetamide in the presence of H2O and
catalysts (ZnL) with heat.
In order to determine whether the reaction between Zn-ligand and amide compound
occurred, the 1H NMR spectra for the amide starting material and benzylamine were taken as
reference spectra. We examined the hydrolysis of benzylacetamide using four Zn-ligand
complexes, ZnCl2 and an Al3+ compounds in a 1:1 mixture of water and DMSO-d6 (for solubility
and NMR locking purposes). The data is shown in Table 3.1.
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Table 3.1. Hydrolysis attempts for benzylacetamide in the presence of various catalysts.
Complexes

Temperature (°C)

Time

Result

Zn(L1)

60-100

>2 weeks

No hydrolysis

Zn(L2)

100

> 3 weeks

No hydrolysis

Zn(L3)

100

> 3 weeks

No hydrolysis

ZnCl2

100

> 3 weeks

No hydrolysis

Zn(L4)

100

> 3 weeks

No hydrolysis

Al(NO3)3·9H2O

100

> 3 weeks

Some hydrolysis

Unfortunately, none of the zinc complexes tested showed clear evidence for C−N bond
cleavage under the reaction conditions studied. Using Al3+ in the form of aluminum nitrate
nonahydrate, Al(NO3)3·9H2O, some hydrolysis was observed after extended heating in pure D2O,
rather than a mixture of DMSO and water. These results highlight the stability of amide bonds
and show that while the zinc complexes studied in this work may be structural models for the
enzymes of interest, they are not functional mimics of hydrolase enzymes. Although the identity
of the atoms in the 1st coordination sphere are the same or similar as in HDAC and other
hydrolyase enzymes, the exact positioning of these atoms are most likely not the same. In
addition, though Zn2+ is important to catalysis, the enzyme catalytic active site provides catalytic
amino acid residues positioned in ideal locations to interact with the substrate and lower
transition states through acid-base interactions. In our complexes, these additional residues are
not present, so the substrate has to compete with other ligands to bind to the metal and likely has
much higher reaction barriers to overcome. These are major reasons why trying to mimic
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enzyme active sites with small molecules is so challenging
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Figure 3.1. 1H NMR spectra of the hydrolysis reaction mixture of amide substrate and
Zn(L2) in DMSO, in the presence of water and heat. Spectrum in black was collected after 24
h and the spectrum in red was collected after 3 days in an oil bath (100 ºC). Comparing these
spectra with the spectrum of benzylamine, it appeared that there was no sign of amine formation.
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Figure 3.2. The 1H NMR spectra monitoring the hydrolysis of amide substrate with
Zn(L3)OH in DMSO, in the presence of water and heat. The spectrum in black was collected
after 24 h and the spectrum in red was collected after 3 days in an oil bath (100 ºC). Comparing
these spectra with the spectrum of benzylamine, it appeared that there is no sign of amine
formation.
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Figure 3.3. The 1H NMR spectra for the reaction of ZnCl2 and amide complex in the
presence of water and heat. The lower spectrum in black was taken at 24 h, and the above
spectrum in red was taken after 3 days in the oil bath. As shown, no evidence of amine product is
present.
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Figure 3.4. 1H NMR spectra monitoring the reaction of Al(NO3)3·9H2O with amide in
presence of water and heat. The mixture was dissolved in D2O (deuterium oxide). Heat was
applied to the reaction with an oil bath (100 ºC) and the spectrum in black was taken of the
reaction after 22 h. The spectrum in red was taken of the reaction after approximately one month.
The appearance of benyzlamine was observed, but complete hydrolysis did not occur even after a
month of heating.
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3.3. Studies of interaction of Zn2+-ligand complexes with inhibitors
3.3.1. Zn(L1) with Vorinostat (SAHA)
Many HDACIs share the same pharmacophore structure shown in Figure 1.4, which
consists of a zinc binding group (ZBG) that chelates the zinc ion, a capping group that caps the
active site binding pocket, and a linker between the ZBG and the cap. One ZBG of interest is the
hydroxamic acid functional group present in SAHA, because of its significant binding ability to
zinc ions. However, inhibitors with these coordinating groups can cause severe toxicity due to
their nonspecific chelation to metals.23,24 Other HDACIs have been discovered that are far more
potent than SAHA, but are also typically more toxic as revealed in in vivo studies.25 SAHA is one
of the most commonly used HDACIs, targeting multiple HDAC enzymes, which makes it
difficult to determine if the therapeutic function and the toxicity of SAHA is a result of nonspecific binding to biological metals or to inhibiting a specific HDAC or a multiple HDACs.26

Figure 3.5. The interaction between Zn2+ in HDAC and the hydroxamic acid group in
SAHA. The ligand with the R group is SAHA, and the two histidine and asparagine groups are
residues in the HDAC active site coordinating to the hydrolytically active Zn2+ ion.
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By using computational chemistry (DFT and QM\MM calculations), Chen and coworkers studied the binding of various HDAC inhibitors and Zn2+.27 The results showed that the
hydroxamate group has a pKa of 9.4 in solution, and that the aliphatic linker has the ability to
form van der Waals interactions with the pocket.14 When performing experiments with the goal
of forming Zn(L1)(SAHA), we considered several approaches and analyzed the products via 1H
NMR, UV-Vis, IR and fluorescence spectroscopies. The first approach was to deprotonate
SAHA by adding 1 equivalent of base (KOH and 18-crown-6), and then add 1 equivalent of
[Zn(L1)]2 in methanol. The reaction was stirred for 24 hours, but no Zn−SAHA product was
formed, as determined by IR and 1H NMR spectra. The second approach was to dissolve 1
equivalent of [Zn(L1)]2 and 1 equivalent of SAHA in acetonitrile and heat the reaction at 60 ˚C
for 24 h. There was some shifting in the 1H NMR spectra, but no clear evidence of product
formation. Therefore, the final approach was to elevate the temperature of the oil bath to 100 ˚C
for the same reaction. A white solid was formed, and a 1H NMR spectrum was taken. Although
there was change in 1H NMR spectra, the overlapping between the signals of the ligand and the
inhibitor made it hard to determine if Zn binding with SAHA has occurred.
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Figure 3.6. 1H NMR spectra of Zn(L1) and SAHA at 60 ˚C for 24 h. The spectrum in black is
for the Zn(L1) with SAHA before heating. The spectrum in red is for the Zn(L1) with SAHA
after 40 h under 60 ºC. As indicated before, spectral changes occurred, but the overlapping
between signals in the spectra makes it hard to identify the binding between the Zn2+ and SAHA.

3.3.2. Zn-Ligand interaction with 8-hydroxyquinoline (8HQ)
8-hydroxyquinoline is a well-known strong metal ion chelator with a rich diversity of
biological properties that has been shown to be an inhibitor of HDAC2. 8-Hydroxyquinoline
binds Zn2+ through the phenolic oxygen anion and the pyridinic nitrogen (Figure 3.7).
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Figure 3.7. 8-HQ interaction with Zn2+ in an HDAC Active Site.
Reaction between Zn(L1) and 8HQ was studied by combining them at 60 ˚C. 1H NMR
spectra were collected (Figure 3.8), and as shown in the spectra, a broad signal appeared at 2.23
ppm, corresponding to water formation with no other major changes observed. The color of the
solution changed to yellow, indicating that 8HQ was reacting. However, 1H NMR spectroscopy
did not reveal clear evidence of 8HQ coordinating to the zinc complex. The signals for the 8HQ
and the Zn(L1) did not shift appreciably enough to make a clear conclusion.
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Figure 3.8. 1H NMR spectra for Zn-L1 interaction with 8HQ in ACN. The black spectra
were taken before heat was applied to the reaction, the red spectra for the reaction after 21 h in
oil bath 60 ˚C, the blue spectra for the reaction after 3 days in oil bath and the green spectra was
for the reaction after one week in oil bath. The mixture was yellow before heat applied and the
color started to change gradually until it turned to orange.

3.4. Computational studies of the interaction of AHA and Zn(L1)
Ab initio calculations were performed with the Gaussian 2009 program package.27 Two
zinc complexes were optimized using HF (Hartree-Fock) as well as DFT (Density Functional
Theory) levels of theory with a B3LYP functional. Both approaches used a 3-21G basis set.28
The zinc ion was first bound to the bis(phenolato)amine and methylamino-N,N-bis(2-methylene)
as shown in Figure 3.9. These ligands are models for L1, but without the tert-butyl substituents
in order to reduce computational time. Both complexes were successfully optimized in
reasonable conformations. Moreover, the optimized Zn-ligand complexes have at least one or
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two open sites that could bind with the inhibitor, to form complexes with a tetrahedral or higher
geometry.
Bonding of the zinc complexes to an inhibitor was examined with deprotonated
acetohydroxamic acid (AHA) as the inhibitor, a small molecule analog of SAHA. As with
SAHA, AHA is a bidentate inhibitor that complexes the Zn2+ in the HDAC active site through
both hydroxamate oxygen atoms. The binding modes that were optimized are shown in Fig 3.10,
and the binding energy of each mode was found. The binding mode of the AHA anion in models
A and D is mono-dentate, whereas in models B and C, the binding is bidentate. In Table 3.2, the
basis set superposition error (BSSE) and the binding energies of Zn2+ and the ligand are reported.
BSSE-corrected energies of all models differ in terms of the binding structures. In addition,
Hartree–Fock calculations are known to underestimate the electron correlation in the molecule;
thus, this method may provide incorrect numbers, but is useful to examine in terms of general
trends between different complexes. Using HF, models A and D share the same bonding energy
of 45.35 kcal/mol. The highest binding energy that was calculated in the HF method is of model
C. On the other hand, in the DFT/B3LYP method, model A has the highest energy 73.92 kcal/mol
and the lowest number is model D with 45.85 kcal/mol. The DFT/B3LYP approach would be
expected to be more accurate than HF, so these numbers are likely closer to the real values. The
distances between Zn and O’s in models A, B and C are between 2 to 3 Å. It should be noted that
models A and D have different distance between the metal and the O in the amide group. In most
hydroxamate complexes characterized by X-ray crystallography, the metal-OC bond is longer
than metal-ON bond. However, the magnitude of the difference is different among different
metal complexes.29
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Figure 3.9. Two different models of the Zn(L) species: Zn(2,2'[[(phenylmethyl)imino]
bis(methylphenol)]) (Zn-L(Me) (1) and Zn (2,2'[[(methyl)imino]bis(methylphenol)] ZnL(Ph) (2). Both complexes shown were calculated in gas phase via HF level of theory with a 321G basis set. Atoms are labeled by color, where red atoms are O, blue atoms are N, purple is the
Zn2+, gray are C atoms, and white are H atoms.
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Figure 3.10. Four different models of the Zn-Ligand-AHA species. A) HF optimized
structure, AHA C-O site bonding with Zn-L complex (1), B) HF optimized structure, AHA C-O
site bonding with (ZnL) complex (2), c) HF optimized structure, AHA N-O site bonding with
(ZnL) complex (1) and D) HF optimized structure, AHA C-O site bonding with (ZnL) complex
(2). The DFT/B3LYP structures were similar, but with slightly different distances.
Table 3.2. BSSE-corrected Binding Energies of Zn2+ and the ligand

HF/3-21G
B3LYP/3-21G

Zn-L(Me) (1)
kcal/mol
213.49

Zn-L(Ph) (2)
kcal/mol
213.47

126.07

131.75
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Table 3.3. BSSE-corrected Binding Energies of Zn-Ligand complexes with

Chelating

Model A
kcal/mol
Monodentate

Model B
kcal/mol
Bidentate

Model C
kcal/mol
Bidentate

Model D
kcal/mol
Monodentate

HF/3-21G

45.35

44.42

49.21

45.35

B3LYP/3-21G

73.92

68.63

73.50

45.85

Table 3.4. The distances between Zinc and the AHA oxygens.
HF/3-21G (Å)

B3LYP/3-21G (Å)

Zn-L AHA

Zn-ON

Zn-OC

Zn-ON

Zn-OC

Model A

4.59

2.69

1.91

2.56

Model B

2.82

1.99

2.11

1.99

Model C

2.02

3.42

1.92

2.05

Model D

4.59

1.97

4.662

1.95

In conclusion, several structural mimetic complexes of HDAC were synthesized and
characterized. These complexes were found not to be functional mimetics of HDAC because
they show no activity towards hydrolyzing amide bonds. However, Al(NO3)3·9H2O was used as
an alternative metal to hydrolyze amide bonds without the presence of a supporting multidentate
ligand. The interaction of zinc complexes and inhibitors were examined by 1H NMR, but the
spectra were hard to analyze due to the overlapping signals. This indicates that the 1H NMR is
not an ideal choice of spectroscopy to study the interactions. As shown in the following chapter,
UV-Vis and fluorescence spectrometry were found to be more promising. Finally, a
computational study of Zn(L1) was performed by using two different approaches HF and
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DFT/B3LYP, both using the 3-21G basis set. Calculations were performed on the interaction
between Zn-Ligand compounds and AHA. Four different models were optimized and their
binding energies were determined. The computational data reveal that the inhibitor (AHA) binds
the metal most favorably in a bidentate fashion. However, given the low basis set and the use a
gas phase conditions, the numbers in this study cannot be directly compared to experimental
information. The binding affinities of the ligands and inhibitor to Zn2+ need to be calculated by
using more advanced methods (functional benchmarked for zinc complexes, larger basis sets,
solvation models, etc.) to obtain values that can be directly comparable to experimental data.
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Chapter 4. Examining the binding between Zn+2 and ligands and inhibitors using UV-Vis and
fluorescence spectroscopies
4.1. Determining the binding affinities between the Zn2+ and ligands and Zn-ligand complexes
with inhibitors using UV-Vis spectroscopy
4.1.1. Introduction
UV-Vis spectroscopy is a common technique to monitor molecular interactions or
chemical reactions. In spectroscopically monitored titration experiments, the association constant
(Ka) between a ligand and a metal ion can be determined from changes in the parameters of the
spectra, such as wavelength of maximum absorbance (λmax) and molar absorptivity (ε). 30
Typically, a titration is performed by holding the concentration of one species constant (in our
case the Zn-ligand complex), while increasing the concentration of the other species (Zn2+),
keeping overall volume nearly the same. In our studies, we applied this concept to determine the
association constant between Zn2+ and a ligand from the spectra after adding one aliquot of a
Zn2+ source to a Zn-ligand complex in solution.
The basis for this type of analysis is Beer’s Law, applied at the λmax of the absorption of
the Zn-ligand complexes.
Beer’s Law is defined as:
𝐴 = 𝜀𝑏𝑐

(1)

In which A is the absorbance (unitless, sometimes called “arbitrary units”), ε is the molar
absorptivity with units of L mol-1 cm-1, b is the path length of the sample (which is 1 cm for all
samples), and c is the concentration of the compound in solution in mol L-1. Note that 𝜀 is
dependent on the wavelength selected for a measurement, and will be different for a different
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wavelength even if all else is constant. Given a constant cell path length and the same
wavelength of absorption, the absorbance will be linearly related to the concentration of the
species under study if Beer’s Law is valid. Beer’s Law is only valid in the so-called “linear
regime”, where absorbance varies linearly with concentration. This relationship breaks down as
absorbance increases above ~1.0. In general, this is because so little light is transmitted that
changes in the amount transmitted are difficult to determine. Further discussion of the details of
Beer’s law and the non-linearity issues will not be covered in this thesis.
The binding or association constant (Ka) corresponds to the reaction Zn2+ + L ⇌ ZnL and
can be easily determined if the concentrations of all components are known at equilibrium.
Given that all of the individual concentrations of the species are difficult to determine in a
complex solution mixture, we can consider the opposite reaction, which occurs when Zn(L) is
dissolved in solution (see table 4.1), to obtain the Ka value. The process is explained in the
following text. If the formal concentration of the zinc-ligand complex in solution is [𝑍𝑛𝐿] = 𝐶0 ,
and the concentration change upon dissociation is [ZnL] = −x , then the final concentration
when dissolved in solution will be [ZnL] = C0 − x.
ZnL ⇌ Zn2+ + L
Table 4.1. The concentration of each product and reactant in the equilibrium reaction.
(ZnL)

Zn2+

L

Expected concentration (C◦)

C◦ (known)

0

0

After equilibrium shift upon
dissolving in solution
The equilibrium
concentration

-x

+x

+x

C◦ -x

x

x
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In this study, the change in initial concentration the Zn(L) complex is reflected in the absorbance
according to Beer’s Law:
𝐴1 = 𝜀𝑏(𝐶0 − 𝑥)

(2)

Where the value A1 is the absorbance observed after Zn(L) was dissolved in solution. This
absorbance is a result of the actual concentration of Zn(L) and x is the concentration of the
dissociated amount of Zn(L) in solution. We are assuming that when a Zn(L) species is added to
solution, some of the ligand dissociates according to Zn(L) ⇌ Zn2+ + L. When adding an excess
of an additional Zn2+source such as ZnCl2, Le Chatlier’s principle should result in re-forming all
of the Zn(L) species. The Beer’s Law equation will then become:
𝐴2 = 𝜀𝑏(𝐶° ) (3)
Where A2 is the absorbance after sufficient amount of Zn2+ is added to drive all free ligand to
completely form (ZnL). Therefore, the change in absorbance (ΔA) between the absorbance of
just Zn(L) (A1) and the absorbance after adding Zn2+ to Zn(L) (A2) will be:
∆𝐴 = 𝐴2 − 𝐴2 = 𝜀𝑏(𝑥)

(4)

The molar absorptivity (ε) of the starting Zn(L) complex at the wavelength used is necessary for
concentration calculations and be determined as follows:
𝜀=

𝐴2
𝑏𝐶0

(5)

Once the molar absorptivity for a complex is obtained at the specific wavelength of study, the
change in absorbance can been used to find the chance in concentration (x), using equation (6):
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𝑥=

∆𝐴

(6)

𝜀𝑏

In order to calculate the binding constant Ka, the increase of absorbance after adding Zn2+
was obtained by subtracting the absorbance of the (ZnL) from the absorbance after additional
Zn2+. The Ka was estimated by using the equations above and Table 4.1 combined in the
equilibrium expression:

𝐾𝑎 =

(𝑍𝑛(𝐿))
(𝑍𝑛2+ )(𝐿)

=

𝐴
( °)

(

𝜀𝑏
∆𝐴 ∆𝐴
)( )
𝜀𝑏 𝜀𝑏

𝐴 .𝜀

°
𝐾𝑎 = (∆𝐴)
2

(7)

(8)

Acetonitrile (ACN) was used as a solvent in some of the reactions due to the favorable
short wavelength cutoff of 190 nm.30 All of the components in this study are soluble in ACN. In
some cases, it was possible to use the same buffer solutions used in previous ITC experiments.16
Analysis of the data was performed using Origin Lab software.
In addition to examining the (ZnL) interaction, we also examined the Zn-ligand
interaction with inhibitors using UV-Vis spectroscopy and fluorescence spectroscopy. The
chapter is divided in two sections based on the two approaches (UV-Vis and fluorescence
spectroscopies) through which the interaction between Zn2+ and the ligands and between the Znligand complexes and the inhibitors were analyzed.
4.1.2. UV-Vis spectra for the interaction between Zn2+ and ligands
UV-Vis spectroscopy was used to examine zinc with several ligands. As shown in table
4.2, the binding constant Ka values were generally in the range of 105–107 M-1 with a few
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outliers. The binding constant for BPA (L2) in buffer was close to the values from ITC, which
validates our results from this absorbance study.16 This also confirms that the affinity of the
ligand to bind with Zn2+ is strong enough to be stable in further reactions with inhibitors.
Table 4.2. Binding values between zinc and ligands studied using UV-Vis spectroscopy.
Solvent Co(M)
Zn(L1)
Zn(L2)

Zn(L4)
+(ZnCl2)
Zn(L4)
+Zn(OAc)2

∆A

A2

ε

x (M)

ZnCl2
(mg)

Ka (M1
)

λmax
(nm)

ACN
Buffer
Buffer
Buffer
Buffer
ACN

0.0010 0.011
0.0010 0.029
0.0020 0.0093
0.0050 0.061
0.50
0.14
0.0020 0.068

1.26
1.48
2.57
2.95
2.95
1.69

1300
1700
1300
5700
5.5
810

9.4×10-6
2.0×10-5
7.3×10-6
1.0×10-4
2.5×10-2
8.0×10-5

7.0
7.0
7.0
7.0
7.0
7.0

1.2×107
3.3×106
3.7×107
4.2×105
6.9×102
2.9×105

280
260
260
260
260
250

ACN

0.0020 0.0015

1.31

660

2.3×10-6

7.0

3.8×108

250

In general, each spectra of each Zn component increases after adding an excess amount
of Zn2+ and the maximum absorbance increases, corresponding with an increase in the
concentration of the species. Notably, the absorbances of these compounds showed some
differences. In Figure 4.1, the UV-Vis spectra of Zn(L1) showed one major absorbance.
However, in Figure 4.2 there are multiple different peaks for Zn(L2)Cl2 in the absorbance. This
is because of the overlapping in absorptions that happen at different electronic states. As shown
in Figure 4.1 the λmax absorbance for Zn(L1) is at 280 nm. After adjusting the baseline, the
absorbance spectrum was increased by 0.011 after the addition of ZnCl2. Therefore, using
equation (7), the association constant Ka is 1.2×107 M-1, if we take into account the 1:1 binding.
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Absorbance (unitless)
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Figure 4.1. The UV-Vis spectra of Zn(L1). The λmax = 280 nm and the absorbance spectra of
the Zn(L1) dissolved in 5 ml acetonitrile has an absorbance of 1.29 (black). The red spectra show
absorbance (with a value of 1.32) after adding ZnCl2 (7.0 mg) at the same λmax.

54

B

A
3.0
1.5

Absorbance (unitless)

Absorbance (unitless)

2.5

1.0

0.5

0.0

2.0

1.5

1.0

0.5

0.0
-0.5
230

240

250

260

270

280

290

300

230

240

250

Wavelength (nm)

260

270

280

Wavelength (nm)

C
D
3.0
3.0

2.5

Absorbance (unitless)

Absorbance (a.u)

2.5

2.0
1.5
1.0
0.5
0.0

2.0
1.5
1.0
0.5
0.0

-0.5
230

240

250

260

wavelength (nm)

270

280

-0.5
220

230

240

250

260

270

280

290

300

Wavelength (nm)

Figure 4.2. UV-Vis spectra of Zn(L2) with concentrations of 1 mM, 2 mM, 5 mM and 500
mM (A, B, C, and D, respectively). Spectra in black show the asborbance of Zn(L2), with
absorbances are at 1.69, 2.55, 2.89 and 2.89 respectively. The red spectra show the absorbance of
Zn(L2) with the additional of ZnCl2, with absorbances at λmax increasing by 0.05, 0.004, 0.07 and
0.16 respectively. All products were disoloved in 5 ml buffer.

The equilibrium association constant obtained from ITC experiments for Zn(L2) (2.4×107 M-1)
was close to those obtained by UV-Vis experiments.16 With increasing the concentration of
Zn(L2), the absorbance increases, because of Beer’s Law. However, at higher concentrations
Beer’s law may not be valid.30 Four concentrations of Zn(L2) were examined in buffer:1 mM, 2
mM, 5 mM and 500 mM. All spectra showed λmax of 260 nm with increasing values of
absorbance. The Zn(L2) shows a Ka of 3.3×106 M-1, 3.7×107 M-1, 4.2×105 M-1 and 6.9×102 M-1,
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respectively from these four concentrations. The Ka values derived from runs with absorbances >
2 are probably incorrect due to deviations from Beer’s Law. At these high absorbances, the
percent of total transmitted light becomes very low, so attempting to observe accurate changes in
the amount of that light is not possible.
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Figure 4.3. The UV-Vis spectra of Zn(L4) . The λmax is 250 nm and the absorbance at λmax is
1.62 (black). The addition of Zn2+(red) as ZnCl2 increases the spectra by 0.070 at the same
wavelength (plot on the left). The spectra on the right, show the spectra of Zn(L4) at the same
concentration, but with added Zn(OAc)2. The λmax is 250 nm and the absorbance increases by
0.01.

We were curious to see how different zinc salts might affect the UV-Vis measurements.
When ZnCl2 was used with Zn(L4), the Ka was ca. 2.9×105 M-1. However, with the addition of
Zn(OAc)2, the absorbance increases by 0.018 and the association constant was 3.8×108 M-1,
higher in value than using ZnCl2. These numbers are estimates, and show that care must be taken
when making comparisons between systems to use the same zinc source. In addition, large
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absorbance values (> 1) have so little transmittance that the numbers become less accurate and
Beer’s law may not be valid. Therefore, these numbers should be calculated again with more
dilute solutions in future studies. The rows in Table 4.2 with final absorbance values above 2 are
likely not useful runs.
In order to check our assumption that adding Zn2+ resulted in complete reformation of
Zn(L), we calculated the amount of dissociation of Zn(L) in the presence of ZnCl2 using the Ka
values we obtained (see Table 4.2). The equilibrium reaction is shown below, along with table
4.3, which includes a term for the concentration of added Zn2+ (z).
Zn2+ + L ⇌ ZnL
Table 4.3. The concentration of each product and the reactant in the equilibrium reaction
after adding ZnCl2.
The concentrations after
adding ZnCl2
After equilibrium shift upon
dissolving in solution
The equilibrium
concentration

Zn2+
z

Ligand
0

(ZnL)
Cₒ

+y

+y

-y

z+y

y

Cₒ-y

Therefore, the equilibrium expression for Ka from the values in Table 4.3 will be:
𝐶 −𝑦

°
𝐾𝑎 = (𝑧+𝑦)(𝑦)

(9)

For our UV-Vis analysis to be correct, we need to know that y is sufficiently small compared to
Cₒ. Assuming y is small compared to Cₒ and to z, we can simply and solve for y according to the
following relationship:
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𝑦=𝐾

𝑧

𝑎 .𝐶°

(10)

This allows us to check that our approach would work by verifying that y is very small compared
to Co. Table 4.4 shows the results of this analysis, including the % value of y compared to Co. As
can be seen, the % value of y compared to Co is always less than 1%, verifying that our
assumption was valid. In other words, the amount of Zn2+ added was enough to ensure that the
ZnL species were completely reformed in our UV-Vis studies.
Table 4.4. The concentration values after adding an excess amount of ZnCl2.

Zn(L1)
Zn(L2)

Zn(L4) +(Zncl2)
Zn(L4) +Zn(OAc)2

z (M)

C◦(M)

x (M)

y

%

0.010
0.010
0.010
0.010
0.010
0.010
0.010

0.0010
0.0010
0.0020
0.0050
0.50
0.0020
0.0020

9.4×10-6
2.0×10-5
7.3×10-6
1.0×10-4
2.5×10-2
8.0×10-5
2.3×10-6

8.5×10-7
3.0×10-6
1.4×10-7
4.8×10-6
2.9×10-5
1.8×10-5
1.3×10-8

0.085
0.30
0.0068
0.096
0.0058
0.88
0.00065

4.1.3. UV-Vis spectra of interactions between (ZnL) and inhibitors
In this section the interaction between (ZnL) and inhibitors were studied using UV-Vis
spectroscopy. Because of the UV-Vis spectra of isolated (ZnL)-inhibitor structures are not
known, the binding constants could not be obtained, but qualitative changes in the spectra were
observed. In order to find Ka values, the stoichiometry of the reaction with inhibitors as well as
the molar absorbtivities of the ZnL-inibitor ternary complexes would be needed.
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Table 4.5. UV-Vis spectra of (ZnL) and inhibitors species.
Complex

∆A

Cᵒ
(mM)

Inhibitor
(mg)

λmax
(nm)

Zn(L1)-SAHA

0.58

0.050

3.0

240

Zn(L1)-8HQ

2.4

0.050

7.0

308

3.0

Absorbance (unitless)

2.5
2.0
1.5
1.0
0.5
0.0
-0.5
250 260 270 280 290 300 310 320 330 340 350 360 370

Wavelength (nm)

Figure 4.4. UV-Vis spectra of Zn(L1)(8HQ) and 8HQ with the addition of Zn(L1)(8HQ) in
ACN at a concentration of 0.050 mM. The black spectrum represents 8HQ alone, and the λmax
is 308 nm with an absorbance of 2.36. The addition of Zn(L1)(8HQ) (red), results in an increase
in the spectra by 0.11 at the same wavelength, as well as the appearance of new peaks.

In order to examine the reaction of Zn(L1) for 8HQ, the UV-Vis spectra were taken for
the 8HQ as well as a combination of Zn(L1) and 8HQ. In Figure 4.4, the black spectrum of
shows a λmax of 308 nm and an absorbance value of 2.36. The spectrum of Zn(L1)(8HQ) was
significantly different from that of just Zn(L1), indicating that we likely formed a complex
between Zn(L1) and 8HQ. However, the identity of the species is unknown based solely on this
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UV-Vis data and the NMR data in chapter 3. We hope that X-ray crystallography can be used in
the future to determine the structure of the compound.
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Figure 4.5. The UV-Vis spectra of Zn(L1)(SAHA) (black) and with addition of SAHA (red)
in ACN. For the black spectrum, the λmax is 241 nm and the absorbance at λmax is 0.68. The
addition of 8HQ (red), as 8HQ increases the spectra by 0.55 at the wavelength 240 nm.

Likewise, the interaction between Zn(L1) and SAHA was examined by using UV-Vis, at
a concentration of 0.05 mM, the absorbance spectrum was obtained with a λmax = 241 nm. Upon
addition of SAHA the absorbance at 241 nm was increased by 0.5. The association constant for
this reaction could not be calculated due to the unknown stoichiometry of the resulting complex
Zn(L1) and SAHA and the unknown molar absorptivity.
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Figure 4.6. UV-Vis spectra of Zn(L2) and 8HQ. The spectrum in black indicates the
absorbance of the Zn(L2) and 8HQ in concentration of 0.05 mM and the spectrum in red
indicates the absorbance after the addition of 8HQ. For the black spectrum, the λmax is 307 nm
and the absorbance at λmax is 1.57. The addition of 8HQ (red), as 8HQ increases the spectra by
1.15 at the wavelength 308 nm.

The interaction between Zn(L2)Cl2 and 8HQ was studied using UV-Vis spectroscopy. The UVVis spectra show that the absorbance of the complex Zn(L2) and 8HQ was increased by 1.2 after
adding a fixed amount of 8HQ (2.0 mg), but the data does not provide any insight into clear
binding. Given the limited data that could be obtained from the UV-Vis studies of inhibitors
reacting with the zinc complexes, we therefore turned to fluorescence spectroscopy.
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4.2. Examining the binding of Zn2+ with ligands and inhibitors by using fluorescence
spectroscopy
4.2.1. Introduction
Fluorescence is defined as the emission of photons from an excited energy states as the
system returns to a lower electronic state, such as in 𝑆1 → 𝑆0 (Figure 4.7). If a certain species can
absorb a specific energy of electromagnetic radiation, its electrons will be driven to a higher
energy states (excitation). The absorbance as a function of wavelength yields an absorbance
spectrum. However, these higher electronic energy states are unstable. Thus, the excited
electrons will decay to their original lower energy states, which can result in the emission of light
if they undergo a luminescence process. It should be noted that the wavelength of fluorescence
emission should be higher than the absorbance wavelength, because the energy in the emission
process is lower than in the absorbance process (some energy is always lost to relaxation
processes that do not emit UV-Vis radiation).31 In other words, the energy of the emitted light is
always lower than the absorbing light because of the relationship between energy and
wavelength:
𝐸=

ℎ𝑐
𝜆

(9)

In which E is the photon energy, λ is the wavelength (nm), h is the Planck constant and c is the
speed of light. Each photon released has its characteristic energy and it can be determined by
subtracting the energy of the excited state and the energy of the ground state. Therefore, the gap
between energy levels defines the photon energy. The fluorescence spectrometry for Zn-ligands
is determined by the π – electrons of the conjugated organic ligand, because zinc does not have
fluorescence character in the UV-Vis regions.32 Fluorescence experiments were conducted to
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study the interaction between 8HQ and SAHA with various ligand-Zn2+ binary complexes that
had been identified as potential HDAC functional mimetics based on the ligand and Zn2+ ITC
and UV-Vis studies. All complexes were dissolved in DMSO in very small amounts (sometimes
the solution needed to be further diluted in order to detect the fluorescence emission signal on the
scale of the spectrometry). Due to the small amounts used and the limits of accuracy on the
balances, we did not determine the concentration of the solution. The data is presented without
normalization, which may exaggerate the comparison of emission intensities. Because
quantification was not possible, only qualitative changes in emission spectra were examined.

Figure 4.7. Example Jablonski diagram for organic dyes: IC—internal conversion, ESA—
excited state absorption, ISC—intersystem crossing.3
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4.2.2. Fluorescence spectra of Zn-ligand and inhibitor interactions
Three wavelengths were selected for fluorescence excitation: 240 nm, 260 nm, and 310
nm. The first two are excitations in the UV region where most of the compounds have
absorption, and the 310 nm corresponds to absorption peaks in some of the Zn(L) complexes.
These three values were kept consistent in order to make qualitative comparisons of the emission
spectra. The fluorescence spectrum of the SAHA inhibitor was first obtained in order to compare
with the zinc complexes (Figure 4.9). At an excitation 310 nm, a weak emission at λmax = 479 nm
is observed (blue). Exciting at 240 nm yields no detectable emission. At an excitation of 260 nm,
the spectrum displayed “negative emission”, which is not an emission of SAHA, but rather likely
noise. Both the positive and “negative” fluorescence intensities were very small.
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Figure 4.8. The fluorescence emission wavelengths of free SAHA at excitation wavelengths
240, 260 and 310 nm.
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The fluorescence emission spectrum of Zn(L1) and SAHA was then recorded. The
reaction was prepared by dissolving both compounds in DMSO. In the Figure 4.10, at excitation
wavelength of 240 nm, the emission maximum was at 375 nm. The sharp peak observed at 484
nm is an artifact of the data collection. Often, sharp peaks are the harmonic of the excitation
spectrum or other artifacts, and should not be considered to be emissions from the excited
compounds. Exciting at 260 nm (not shown) resulted in no detectable emission. Exciting at 310
nm resulted in a sharp peak at 572 nm (likely an artifact) and a broad emission at 425 nm. The
peak at 572 nm was observed as an unidentified artifact in several of our fluorescence spectra.
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Figure 4.9. The Fluorescence spectra of Zn(L1) and SAHA interaction. The spectrum in red
shows the emission in 310 nm, and the spectrum in black shows an emission with excitation at
240 nm.
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The Fluorecsence spectra of Zn(L2), shown in Figure 4.11, showing one emission peak at
496 nm upon excitation at 240 nm. At 260 nm there was no observed emission, and at 310 nm
three peaks were observed at 401 nm and 337 nm, as well as an artifact at 570 nm (Figure 4.10).
When 8HQ was used as the inhibitor with Zn(L2) in DMSO, shown in Figure 4.12, emission
peaks were observed at all 3 excitation wavelengths studied. At an excitation of 240 nm, only a
small emission at 530 nm was observed. However, at 260 nm excitation, strong emission was
observed at 492 nm. At 310 nm excitation, the emission at 492 nm moved to 482 nm, and small
emission appeared at 344 nm as well. At excitation with 260 nm, Zn(L2) did not show emission.
However, Zn(L2)(8HQ) shows two different emission peaks at higher wavelengths at this
excitation. The fluorescence spectrum of free 8HQ (Figure 4.12) does not show the same peaks
seen at all three excitations of Zn(L2) with 8HQ. Comparing emission of 8HQ and emission of
Zn(L2)(8HQ), we can determine that there is some form of binding between Zn(L2) and 8-HQ
based on the qualitative emission changes. In addition, these emission spectra were different
from the emissions of just Zn(8HQ)2 (Figure 4.15).
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Figure 4.10. The fluorescence emission of Zn(L2) at excitations of 240 nm and 310 nm. An
emission is observed at 400 nm upon excitation at 310 nm.
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Figure 4.11. The fluorescence spectra of Zn(L2) with 8HQ in DMSO. Three emission spectra
were observed after exciting the complex at excitations 240, 260 and 310 nm.
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Figure 4.12. Fluorescence spectra of 8HQ. At excitation wavelengths 240, 260 and 310 nm.
The product was dissolved in DMSO. An emission was observed at around 400 nm, but the
spectral window examined did not allow for the peak wavelength to be observed.

When the isolated Zn(L3)OH species was studied in DMSO for fluorescence, the significant
emissions were observed at 240 nm are a large two peaks at 584 and 606 nm (likely a
vibrational progression, Figure 4.14). At 260 nm excitation, an emission at 706 nm was
observed. At 310 nm, only a likely harmonic artifact was observed.
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Figure 4.13. Fluorescence emission of Zn(L3)OH in DMSO at excitations of 240 and 310
nm. An emission was observed at around 400 nm at excitation 240 nm, but the spectral window
examined did not allow for the peak wavelength to be observed. The peak observed at 622 nm is
likely a harmonic of the excitation at 310 nm.
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Figure 4.14. The fluorescence spectra of Zn(L3)(8HQ) in DMSO. Different emission
behavior was observed after exciting the complex in 240, 260 and 310 nm.
The fluorescence spectra of Zn(L3(8HQ) show two major peaks at excitation 240 nm and one
small peak at excitation wavelength 310 nm, along with the double harmonic of the excitation
wavelength. In order to attempt to understand the spectra of Zn(L3)(8HQ), the known
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Zn(8HQ)2 species was studied with fluorescence. Zn(8HQ)2 showed different behavior
compared to Zn(L3)OH and Zn(L3)(8HQ) in that the same emission at 351 nm was observed
at all 3 excitation wavelengths (Figure 4.15). Interestingly, at excitation with λ = 260 nm a
new emission peak appeared at 543 nm as well.
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Figure 4.15. Fluorescence spectra of Zn(8HQ)2. As shown the emissions of all excitations
contain a feature at 351nm. There is also a clear broad peak at 543 nm upon excitation with 260
nm light. Other features are artifacts or harmonic peaks of the excitation wavelengths.
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Figure 4.16. Fluorescence spectra of ZnCl2 and SAHA. Both excitations studied did not result
in significant emission signals (the sharp signals are artifacts).
The fluorescence spectra of the reaction mixture containing ZnCl2 and SAHA were
obtained at excitations 240 nm and 310 nm (Figure 4.16). Unfortunately, there were artifacts in
the emission spectra but no clear major peaks.(similar to the fluorescence spectrum of SAHA).
SAHA is inactive to fluorescence spectroscopy compared to 8HQ, which is likely due to the lack
of conjugation in SAHA as compared to 8HQ.
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Figure 4.17. The fluorescence spectra of Zn(L4) and 8HQ at excitation wavelengths 240,
260 and 310 nm. A major feature at 550-560 nm is seen at excitations of 260 and 310 nm.

In Figure 4.18, the fluorescence spectra of Zn(L4) and 8HQ at all three excitation wavelengths is
shown. At excitation with240 nm (black), the spectrum shows no major emission. However, at
excitation with 260 nm, an emission peak was shown at wavelength 551 nm as well as a peak
near 400 nm, and at excitation 310 nm, an emission shows at 555 nm wavelength. Comparing the
fluorescence spectra of Zn(L4) and 8HQ with the fluorescence spectra of free 8HQ, there are
clear differences, indicating that 8HQ can react with Zn(L4).
In conclusion, UV-Vis spectroscopy and fluorescence spectroscopy were used to study
the zinc complexes and their interactions with inhibitors. UV-Vis spectroscopy of the (ZnL)
compounds in the presence of added zinc was used to estimate Ka values, which agreed
reasonably well with ITC values in the case of BPA. However, the absorption values were high,
and should be re-examined under more dilute conditions. Fluorescence was used to examine
inhibitor interactions with zinc complexes, and 8HQ showed strong changes in responses when
coordinated to zinc, whereas SAHA was found to not be very responsive to excitation in
fluorescence spectroscopy. The fluorescence studies of the (ZnL) mimetic complexes and their
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binding with inhibitors provide valuable information. We observed qualitative changes in the
emission spectra of the various complexes in the presence of inhibitors, indicating that reactions
were observed. Fluorescence of Zn(L1) and 8HQ showed emission spectra at 375 nm that was
not observed with free 8HQ. When comparing the emission spectra of the reaction between
Zn(L2) and 8HQ with the emission spectra of free 8HQ (Figure 4.12), the spectra also did not
match. For the interaction between Zn(L3)OH with 8HQ (Figure 4.14), the emission spectra
were different comparing to the emission spectra of free 8HQ or Zn(8HQ)2 (Figure 4.15). Lastly,
the Zn(L4) with 8HQ (Figure 4.17) show emission spectra that is also different than the
fluorescence spectra of free 8HQ or Zn(8HQ)2. We can conclude that Zn(L4) binds to 8HQ in
solution and forms a product that is different than Zn(8HQ)2. The data with SAHA were less
conclusive because of the lack of significant fluorescence response from SAHA. Notably,
quantitative studies of these and related complexes would be more informative, wherein the
concentrations of all species are known and the extinction coefficients of the emission spectra
can be determined. Further studies are also needed to understand the mechanism of the
fluorescence from these compounds. Work toward these goals is ongoing in the Grice lab.
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